The glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) are beneficial for the secondary prevention of ASCVD (4, 5). The gene discussed is GLP1R; the disease is atherosclerosis.